Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying ulcerative colitis, a condition that causes inflammation and sores in the colon and rectum. The study is specifically for children and teenagers aged 2 to less than 18 years who have moderately to severely active ulcerative colitis. The treatment being tested is called mirikizumab, which is also known by its code name LY-3074828. Mirikizumab is available in two forms for this study: a 100 mg solution for injection in a pre-filled syringe and a 300 mg concentrate for solution for infusion. The purpose of the study is to evaluate how effective and safe mirikizumab is for treating ulcerative colitis in young patients.

Participants in the study will receive either mirikizumab or a placebo. The study will observe the participants over a period of time to see if their condition improves. The main goal is to see if mirikizumab can help achieve clinical remission, which means reducing the symptoms of ulcerative colitis, by the end of the study period. The study will also look at how the body processes the medication and monitor any side effects that may occur.

The study is designed to last until 2026, with the recruitment of participants expected to start in December 2023. During the study, participants will receive regular check-ups and assessments to track their progress and ensure their safety. The results of this study will help determine if mirikizumab is a beneficial treatment option for young people with ulcerative colitis.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes reviewing medical history and current health status.

    Participants must be between 2 and less than 18 years old, weigh more than 10 kg, and have moderately to severely active ulcerative colitis.

  2. Step 2

    Treatment initiation

    The treatment begins with the administration of mirikizumab. This medication is provided in two forms: a 100 mg solution for injection in a pre-filled syringe and a 300 mg concentrate for solution for infusion.

    The initial dose is given through an intravenous infusion, which means the medication is delivered directly into a vein.

  3. Step 3

    Subsequent doses

    Following the initial infusion, subsequent doses of mirikizumab are administered as a subcutaneous injection, which means the medication is injected under the skin.

    The frequency and dosage of these injections will be determined by the study protocol and communicated by the healthcare team.

  4. Step 4

    Regular monitoring

    Throughout the study, regular monitoring will be conducted to assess the effectiveness and safety of the treatment.

    This includes scheduled visits for health evaluations, blood tests, and other necessary assessments.

  5. Step 5

    Evaluation at week 12

    At week 12, an evaluation will be performed to determine the response to the treatment.

    Participants who show a clinical response will continue with the treatment regimen.

  6. Step 6

    Final assessment

    The study concludes with a final assessment at week 52 to evaluate the overall effectiveness of the treatment.

    The primary goal is to achieve clinical remission, which means a significant reduction or disappearance of symptoms.

Who can join the trial?

5 criteria

  • Participants must be males or females who weigh more than 10 kg.
  • Participants must be 2 to 18 years old.
  • Participants must have moderate to severe ulcerative colitis (UC). This means their condition is more than mild but not the most severe form.
  • Participants must have tried and not responded to treatments such as corticosteroids (a type of medication that reduces inflammation), biologics (medicines made from living organisms), anti-TNF antibodies (medicines that block a protein involved in inflammation), anti-integrin antibodies (medicines that block certain proteins on the surface of cells), or Janus Kinase (JAK) inhibitors (medicines that block certain enzymes involved in inflammation).
  • Participants must have had UC for at least 3 months before starting the study. This includes having evidence of UC from an endoscopy (a procedure where a doctor looks inside the colon) and a histopathology report (a detailed examination of tissue samples).

Who cannot join the trial?

10 criteria

  • Patients with any other significant health condition that might interfere with the study.
  • Patients who have had a recent infection that required treatment with antibiotics or antiviral medications.
  • Patients who have a history of cancer, except for certain types of skin cancer that have been treated.
  • Patients who have a history of certain diseases affecting the immune system, such as HIV.
  • Patients who are currently using other medications that might interfere with the study treatment.
  • Patients who have had a recent surgery or are planning to have surgery during the study period.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who have participated in another clinical trial recently.
  • Patients who have a known allergy to the study medication or its ingredients.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Mirikizumab is a medication being studied for its potential to help people with ulcerative colitis, a condition that causes inflammation and sores in the colon. This medication works by targeting specific proteins in the body that are involved in the inflammatory process. By doing so, it aims to reduce inflammation and help achieve remission, which means reducing or eliminating the symptoms of ulcerative colitis. The study is focused on understanding how well mirikizumab works, how it moves through the body, and its safety for children and teenagers aged 2 to less than 18 years who have moderate to severe ulcerative colitis.

What is already known about the treatment

Mirikizumab – Mirikizumab is administered as an injection, typically under the skin, and is currently being studied in clinical trials for its effectiveness in treating moderately to severely active ulcerative colitis in children aged 2 to less than 18 years. This medication is still under investigation, and its use is not yet fully established in medical practice. It is primarily indicated for ulcerative colitis, a condition that causes inflammation and sores in the colon. Mirikizumab works by targeting and blocking a specific protein in the body that contributes to inflammation, helping to reduce symptoms and promote remission. It belongs to a class of drugs known as monoclonal antibodies, which are designed to interact with specific targets in the immune system.

Investigated diseases

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon, also known as the large intestine. It is characterized by inflammation and ulceration of the innermost lining of the colon, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The disease typically begins in the rectum and may extend continuously to involve the entire colon. The inflammation causes the colon to empty frequently, resulting in diarrhea. Over time, the inflammation can lead to the formation of ulcers, which are small open sores that can produce pus and mucus. The progression of ulcerative colitis can vary, with periods of active symptoms followed by times of remission.
Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IIITrial ID2022-502183-20-00Protocol codeI6T-MC-AMBAEstimated enrolment60 patientsSponsorEli Lilly & Co.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.